Soleno Therapeutics stock hits 52-week high at 86.84 USD

Soleno Therapeutics (NASDAQ:SLNO) Inc has reached a significant milestone as its stock hit a 52-week high of 86.84 USD, with the company now commanding a market capitalization of $4.37 billion. According to InvestingPro analysis, the stock appears overvalued at current levels, though analysts maintain price targets ranging from $97 to $145. This achievement underscores a remarkable year for the company, with its stock experiencing a substantial 1-year change of 106.19%. The impressive growth reflects investor confidence and positive market sentiment surrounding Soleno Therapeutics’ recent developments and strategic initiatives. InvestingPro data reveals the stock’s unique characteristic of often moving opposite to the market with a beta of -2.67, making it an interesting diversification option. As the company continues to navigate the competitive landscape, this new 52-week high marks a pivotal point in its market performance, attracting attention from both investors and industry analysts. For deeper insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, along with 13 additional ProTips for SLNO.

In other recent news, Soleno Therapeutics has reported new data on its VYKAT XR tablets for Prader-Willi syndrome (PWS), highlighting significant reductions in hyperphagia symptoms among patients with strict food controls. This data was presented at the 2025 United in Hope conference, showcasing the drug’s efficacy and safety, even in patients with pre-diabetes or diabetes. Meanwhile, the company has made strides in its international expansion, with its Marketing Authorization Application for VYKAT XR validated by the European Medicines Agency, paving the way for potential approval in the EU. This marks a significant step for Soleno, which has already secured Orphan Drug Designation in the region. On the analyst front, TD Cowen initiated coverage on Soleno with a buy rating, praising the company’s management and the drug’s market potential. Piper Sandler maintained an Overweight rating, citing positive feedback from a European specialist and the potential for widespread use upon approval. Stifel also retained a Buy rating, noting the promising launch dynamics and strong initial demand for VYKAT in the U.S. These developments underscore Soleno’s growing momentum in addressing the unmet needs of the PWS community.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.